Chart a Different Course for Atopic Dermatitis

Living with atopic dermatitis (AD), also known as eczema, can feel like travelling a road that only leads back to square one. Join others who are exploring a different path for AD in the APG279-101 Study.
See If You May Qualify

You may be able to participate
 in the APG279-101 Study if you:

Are at least 18 years old
Were diagnosed with atopic dermatitis (AD) at least 1 year ago
Haven't seen enough improvement from a topical AD treatment

If you are interested in participating, the study doctor or staff will review additional study criteria with you.

Participants may be reimbursed for travel and expenses.
See If You May Qualify

About the APG279-101 Study

The APG279-101 Study is evaluating the safety, tolerability and pharmacokinetics (what the body does to the drug) of two study drugs compared to a known treatment for adults with AD.

If you participate in this clinical research study, you will be randomly assigned to 1 of 2 study treatment groups:

  • One group will receive the combination of study drugs
  • The other group will receive a known treatment

You will have a 50/50 chance of being placed in either group. The study drugs and the known treatment will be given as subcutaneous (under the skin) injections.

The study will last approximately 20 months and will involve up to 24 visits. You will meet regularly with a dermatologist and other health specialists as part of study participation.
© 2025 Clinical Trial Media. All Rights Reserved. The images contain models and are being used for illustrative purposes only.
Privacy Policy Legal Notice